Health Care Providers Safety Act of 2025
Summary
HR 612 is an early-stage bill authorizing HHS grants for healthcare provider security. It authorizes zero dollars and requires a separate appropriations bill for funding. Market impact is minimal until actual funding is committed.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 612 authorizes but does not appropriate any funding for healthcare security grants.
- 2.Zero dollar amount specified in the bill — market impact depends entirely on future appropriations.
- 3.Cybersecurity vendors (CrowdStrike, Palo Alto, Fortinet) and physical security vendors (Allegion, Schneider) are positioned beneficiaries if funding materializes.
- 4.Bill is in earliest legislative stage with no hearings or committee action — low probability of near-term enactment.
Market Implications
No near-term market implications. This bill does not move any market. No funding has been authorized or appropriated. Investors should monitor whether HR 612 receives a hearing or markup in the Energy and Commerce Committee, which would indicate serious legislative momentum. Until then, the bill is a policy statement with zero financial impact. The recent presidential actions under the Defense Production Act (Apr 20, 2026) are unrelated to healthcare provider security and do not affect this bill's prospects.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Foreign Robocall Elimination Act
Water Cybersecurity Enhancement Act of 2025
Protect Liberty and End Warrantless Surveillance Act of 2026
Cyber Ready Workforce Act
Rural and Municipal Utility Cybersecurity Act
Protect America’s Innovation and Economic Security from CCP Act of 2025
SECURE Grid Act
Streamlining Federal Cybersecurity Regulations Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.